Psoriatic arthritis is a combination of psoriasis and arthritis symptoms. You may have skin and nail changes, joint pain and ...

While pharmacologic therapies remain central to managing PsO and PsA, non-pharmacologic interventions also play a crucial ...

Psoriatic arthritis represents a complex intersection of immune dysfunction where inflammation targets both skin and joints, ...

A 2019 review of studies indicated that about 1 in 4 people who have psoriasis develop psoriatic arthritis (PsA), which causes both sets of symptoms. People with PsA are at a higher risk of ...

Women with psoriasis show shorter drug survival for biologics, including IL-17/23 inhibitors, due to lower satisfaction and ...

Psoriatic arthritis can affect any joint in the body ... % of people with PsA have at least one close family member who has psoriasis or PsA. Additionally, researchers have been able to identify ...

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

The findings highlight the potential benefits of newer biologics targeting IL-12, IL-23, and IL-17 while also raising ...

Long-term extension data show Tremfya (guselkumab) significantly reduced symptoms and inhibited structural joint damage ...

A new cohort study published in Journal of American Medical Association suggests that biologics targeting IL-12, IL-23, and ...

Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Discover a study that assessed the risk of hospitalisation for serious infections based on different categories of systemic ...